Warning: Undefined variable $count in /home/seniorca/public_html/wp-content/themes/divi-news-child-healthcare/index.php on line 40
Warning: Undefined variable $count in /home/seniorca/public_html/wp-content/themes/divi-news-child-healthcare/index.php on line 121
Ocugen Acquires Histogenics Corporation
Ocugen, Inc., a privately held clinical-stage biopharmaceutical company, has acquired Histogenics Corporation (NASDAQ: HSGX). Although no financial terms were disclosed, the merged company will be publicly-traded, operating under the Ocugen name. Ocugen discovers, develops and commercializes a pipeline of innovative therapies that address rare and underserved eye diseases. Histogenics develops a restorative cell therapy technology platform. It has collaborated with Brigham and Women’s Hospital, Cornell University and other leading institutions to advance molecular biology and proprietary materials sciences. Perhaps a big factor driving Ocugen’s purchase is Histogenic’s pipeline... Read More »
Will Catalent’s Deal Launch the Next Wave of CRO M&A?
Contract research organizations (CROs), like contract development and manufacturing organizations (CDMOs), have been popular targets for private equity firms and strategic buyers for years. The deals seem to come in waves, and the healthcare M&A market may be in for a tsunami this year. In 2013, some 20 transactions for CRO/CDMO targets were announced, with some hefty price tags attached. Royal DSM paid $1.95 billion to buy Patheon. Other big deals that didn’t disclose prices came from KKR & Co. (NYSE: KKR), which acquired both PRA International and ReSearch Pharmaceutical Services that year. CRO deal volume rose a little in 2014 (27 deals), then ebbed in 2015 (11 deals). The... Read More »
Health Care M&A Deals, Week Ending April 12, 2019
The Health Care M&A Weekly chart is a selection of transactions announced during the prior week(s). The deals presented here are from our Deal Search Online database, which is updated every business day. Visit www.dealsearchonline.com to see how Deal Search Online can help you stay up-to-date on the healthcare market overall, or in a particular sector of interest to your firm. Behavioral Health Care Acquirer Target Price Principal Real Estate Spezialfondsgesellschaft mbH Privatklinik Friedenweiler clinic N/A Sprout Health Group Endeavor House North N/A Biotechnology Acquirer Target Price Ocugen, Inc. Histogenics Corporation N/A XOMA Corporation Rights to... Read More »
Healthcare Deal Spending Was Healthy in March 2019
March 2019’s combined spending, at nearly $25 billion, is a healthy-looking sum, even though it represents a 24% drop compared with February 2019 and a 65% decline versus March 2018. As usual, March 2019’s total is mostly the result of one deal—Centene’s (NYSE: CNC) $17.4 billion bid for WellCare Health Plans (NYSE: WCG), which accounted for 70% of the total. Without it, March 2019 would have posted a total of $7.5 billion and a 77% decrease from the previous month’s approximately $32.8 billion. And an almost 90% drop compared with the $71.5 billion in March 2018. Spending isn’t the real measure of the health of the healthcare deal market, as we say every month. Sources tell us they see... Read More »
March Healthcare Deal Volume Dribbled Off
It was a slow first quarter, and March’s monthly deal results didn’t change that fact. Just 115 transactions were announced, following February’s total of 106. Compared with March 2018’s 149 deals, last month’s deal volume sank 23%. The over-heated market we saw in 2018 is cooling, at least momentarily. Of course, there was a time when seeing 115 deals in a month was unusual. Dare we say, exciting? But that was so five years ago, to be exact. In March 2014, there were 97 transactions made public, up just a sliver from the 95 announced in February 2014. With the exception of August 2014 (another slow month with 95 deals), monthly deal volume has stayed above the 100-mark ever since.... Read More »
Q1:2019 Healthcare Deal Volume Slowed
Talk of slowing global economic growth has swirled since late last year, following tariffs, trade wars, Brexit and you-name-it. The healthcare M&A market appeared to reflect the fears, as deal volume in the first quarter of 2019 slid 27% compared with the fourth quarter of 2018, and was down 19% compared with the same quarter a year ago. Granted, matching the nearly 500 deals reported in the record-making fourth quarter would be a stretch even in better times. But with preliminary data showing just 362 transactions recorded in the first quarter, we’re certainly looking at a slowdown in healthcare deals. Last year in the same period, 447 deals were announced. We’ve talked with a lot of... Read More »
Healthcare M&A Spending Spiked in Q1:2019
Spending in the first quarter, totaling $149 billion, beat both the previous quarter (up 239%) and the year-ago time period (up 31%). Three deals had a combined total of $113 billion, accounting for 76% of that spending. Without those three, the first quarter would have ended with approximately $36 billion, which would be 18% lower than the fourth quarter of 2018 ($44 billion) and 68% lower than the first quarter in 2018 ($113 billion). Those big deals began coming early on, beginning with the $74 billion acquisition of biotech biggie Celgene Corp. (NASDAQ: CELG) by Bristol-Myers Squibb (NYSE: BMY) on January 3. The deal put Bristol-Myers deeper into the highly competitive and highly... Read More »
Small World: The Week of International Pharma Deals
Last week, the list of pharmaceutical deals announced also could have served as a geography lesson. Not only was the volume of deals particularly high, accounting for nearly 28% of the week’s total, but it had a diverse list of countries. Beginning in the United States, New York City-based Royalty Pharma, which focuses entirely on acquiring royalty interests in marketed and late-stage biopharmaceutical products, acquired the royalty interest in Indianapolis-based Eli Lilly’s (NYSE: LLY) Emgality from Arteaus Therapeutics (Cambridge, Massachusetts) for $260 million. Advanz Pharma Corp. (ADVZ.TO), a Canadian pharmaceutical company, bought the global rights to two drugs for $33.3... Read More »
Advantia Health Jumps into Digital Health
Advantia Health, a physician medical group focused on women’s health, has acquired telehealth company Pacify. The target developed an app that offers virtual perinatal care for new and expectant mothers. It connects them with consultants and registered nurses to complement in-person visits with OB-GYNs, pediatricians and other physicians. The financial terms of the were not disclosed, but it’s easy to see why Advantia acquired the digital health company. Pacify’s app connects patients with consultants and registered nurses to complement in-person visits with OB-GYNs, pediatricians, and other physicians. This deal combines Advantia’s physical physician practices and... Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
